VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ORKA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ORKAOruka Therapeutics, Inc.
$96.32$5.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ORKA logo

Oruka Therapeutics, Inc.

ORKA
NASDAQ · Immunology Biotech
$96.32
At close - Nov 17, 4:00 PM EST - USD
Market Cap$5.81B
P/E-45.2x
52W High$115.52
Volume779.88K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Pre-Revenue Clinical Burn Outpaces Cash Runway for ORKA

Oruka Therapeutics remains pre-revenue, with quarterly R&D expense rising from $18.7M in 2024Q2 to $53.7M in 2026Q3 and free cash outflow widening from -$2.6M to -$44.4M over the same span, suggesting clinical spend is accelerating faster than any operating scale.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsHealthy
Explore valuation models
MARKET ACTION

ORKA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-226% Peers

P/E is 226% below peer median

03

Market leadership

RS 98 · Leader

High momentum (Outperforming 98% of market)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 9

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ORKA+240.71%
S&P 500 (^GSPC)+7.21%
1-Year Return
ORKA+241.20%
S&P 500 (^GSPC)+10.03%
3-Year Return
ORKA+432.58%
S&P 500 (^GSPC)+52.57%
5-Year Return
ORKA+293.46%
S&P 500 (^GSPC)+50.30%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$105M-25.9% YoY
Free cash flow FY25
-$88M-52.4% YoY
Operating margin FY25
-
ROIC (FY25)-24.5%
Avg ROIC 5Y-32.8%
ROE (TTM)-18.7%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 9, 2026
-$0.63-5.1%
vs -$0.60
—
vs —
Q3 2026
Aug 10, 2026
-$0.55-7.3%
vs -$0.51
—
vs —
Q2 2026
May 13, 2026
-$0.48+12.2%
vs -$0.55
—
vs —
Q2 2026
Mar 12, 2026
-$0.45+26.2%
vs -$0.61
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 9, 2026
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A

Defense World·Nov 9, 2026
Oruka Therapeutics, Inc. $ORKA Stock: Candriam S.C.A. Lowers Holdings

Candriam S.C.A. trimmed its holdings in Oruka Therapeutics, Inc. (NASDAQ: ORKA) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 339,032 shares of the company's stock after selling 13,684 shares during the period. Candriam S.C.A. owned about 0.51% of Oruka

GlobeNewsWire·Nov 3, 2026
Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Date: November 10, 2026 Presentation Time: 11:00 AM EST Stifel 2026 Healthcare Conference Date: November 11, 2026 Presentation Time: 4:00 PM EST UBS Global Biopharma Conference Date: November 17, 2026 Presentation Time: 4:00 PM GMT Jefferies Global Healthcare Conference Date: November 18, 2026 Presentation Time: 4:30 PM GMT Webcasts and replays of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

MarketBeat·Oct 27, 2026
Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen achieved complete skin clearance, measured by PASI 100, in 61% of participants at week 16, while 86% achieved PASI 90.

Filtered for Oruka Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark ORKA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Oruka Therapeutics, Inc. (ORKA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ORKA logoORKAOruka Therapeutics, Inc.Current
$96.32$5.81B-45.20——-18.66%—
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$957.76$98.67B20.990.99%28.51%15.07%0.36%
SANA logoSANASana Biotechnology, Inc.
$1.88$523.19M-3.89——-97.08%—
ARQT logoARQTArcutis Biotherapeutics, Inc.
$27.33$3.42B125.0291.34%5.88%14.18%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
ABBV logoABBVAbbVie Inc.
$292.86$517.42B50.148.57%15.68%—2.24%

Compare ORKA vs Peers

Oruka Therapeutics, Inc. (ORKA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs REGN

Most directly comparable listed peer for ORKA.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ORKA against a more recognizable public peer.

Peer Set

Compare Top 5

vs REGN, SANA, ARQT, IMVT

Get notified when ORKA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ORKA Frequently Asked Questions

Oruka Therapeutics, Inc. (ORKA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is ORKA profitable?

No. Oruka Therapeutics, Inc. (ORKA) reported a net loss of $152.6M over the trailing twelve months.

Dividend & Returns
What is ORKA's return on equity?

Oruka Therapeutics, Inc. (ORKA) had a return on equity (ROE) of -18.7% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Oruka Therapeutics, Inc.'s free cash flow?

Oruka Therapeutics, Inc. (ORKA) had negative free cash flow of $123.9M over the trailing twelve months.

What if you invested $1,000 in ORKA back in 2005?

Total return calculator · dividends reinvested · 21+ years of data

See returns →